Jazz Pharmaceuticals
JAZZ
325 hedge funds and large institutions have $8.58B invested in Jazz Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 107 increasing their positions, 118 reducing their positions, and 44 closing their positions.
48% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 44
14% more capital invested
Capital invested by funds: $7.51B → $8.58B (+$1.07B)
7% more funds holding
Funds holding: 305 → 325 (+20)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
9% less repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 118
48% less call options, than puts
Call options by funds: $137M | Put options by funds: $261M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$417M |
| 2 |
CM
Churchill Management
Los Angeles,
California
|
+$50.7M |
| 3 |
Bank of New York Mellon
New York
|
+$40.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$39.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$38.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$50.7M |
| 2 |
PC
PointState Capital
New York
|
-$50M |
| 3 |
Jennison Associates
New York
|
-$49.9M |
| 4 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$45.9M |
| 5 |
HM
HealthCor Management
New York
|
-$40.7M |
JAZZ Hedge Fund Activity: Q3 2014 in Review
325 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2014, worth a combined $8.58B — up 14% from $7.51B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new JAZZ positions and 44 closed out — a net gain of 21 holders — while 107 added to existing stakes and 118 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $417M. The largest seller was Wells Fargo, cutting an estimated $50.7M.
- 325 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2014, up from 305 in Q2 2014.
- Funds reported $8.58B of Jazz Pharmaceuticals stock for Q3 2014, up 14% quarter-over-quarter.
- 65 funds opened new Jazz Pharmaceuticals positions in Q3 2014 and 44 closed out, a net change of +21 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2014 was Fidelity Investments, an estimated $417M added.
- The largest Jazz Pharmaceuticals seller in Q3 2014 was Wells Fargo, an estimated $50.7M sold.
Based on aggregated 13F filings for Q3 2014.